These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 35279606)
21. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis. Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643 [TBL] [Abstract][Full Text] [Related]
22. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis. Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817 [TBL] [Abstract][Full Text] [Related]
23. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis. Panchal SC; Ondo WG Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325 [TBL] [Abstract][Full Text] [Related]
24. Pimavanserin use in a movement disorders clinic: a single-center experience. Mahajan A; Bulica B; Ahmad A; Kaminski P; LeWitt P; Taylor D; Krstevska S; Patel N Neurol Sci; 2018 Oct; 39(10):1767-1771. PubMed ID: 30032332 [TBL] [Abstract][Full Text] [Related]
28. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease. Hermanowicz S; Hermanowicz N Expert Rev Neurother; 2016 Jun; 16(6):625-33. PubMed ID: 26908168 [TBL] [Abstract][Full Text] [Related]
34. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. Nasrallah HA; Fedora R; Morton R Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S; Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684 [TBL] [Abstract][Full Text] [Related]
36. Can pimavanserin help patients with Parkinson disease psychosis? de la Cruz J; Canal C JAAPA; 2019 Jan; 32(1):44-45. PubMed ID: 30589736 [TBL] [Abstract][Full Text] [Related]
37. Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries. Mosholder AD; Ma Y; Akhtar S; Podskalny GD; Feng Y; Lyu H; Liao J; Wei Y; Wernecke M; Leishear K; Nelson LM; MaCurdy TE; Kelman JA; Graham DJ Am J Psychiatry; 2022 Aug; 179(8):553-561. PubMed ID: 35702829 [TBL] [Abstract][Full Text] [Related]
38. Parkinson disease: Pimavanserin could be useful for treating psychosis in Parkinson disease. Kingwell K Nat Rev Neurol; 2013 Dec; 9(12):658. PubMed ID: 24247322 [No Abstract] [Full Text] [Related]
39. Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. Ballard C; Youakim JM; Coate B; Stankovic S J Prev Alzheimers Dis; 2019; 6(1):27-33. PubMed ID: 30569083 [TBL] [Abstract][Full Text] [Related]